Latest news with #MVRamana
Hans India
24-06-2025
- General
- Hans India
Agricultural education aligned with NEP 2020: Associate Dean
Tirupati: Associate Dean of Acharya NG Ranga Agricultural University Dr MV Ramana said that in alignment with the transformations occurring in the Indian agricultural sector and the National Education Policy (NEP) 2020, the Indian Council of Agricultural Research (ICAR) has introduced a revised syllabus aimed at enhancing practical knowledge and creativity among agricultural students. Speaking at the 64th anniversary celebrations of Sri Venkateswara Agricultural College on Monday, Dr Ramana said that the new curriculum is designed to better align agricultural education with the needs of the sector and agri-based industries. He noted that the college has played a vital role in developing skilled human resources for the agricultural sector. 'Till now, this institution has produced 5,144 BSc Agriculture graduates, 1,744 postgraduates, and 240 research scholars who are currently serving in significant roles across government and private sectors, contributing substantially to the progress of Indian agriculture,' he said. Vice Chancellor of SV Vedic University Prof Rani Sadasiva Murthy, who was the chief guest for the event, encouraged students to adapt to the changing dynamics in agriculture. He highlighted the importance of self-employment opportunities and urged students to focus on innovation and problem-solving to address emerging challenges in the field. Dean of Agriculture Dr Ch Srinivasa Rao explained that major changes have been made to the teaching methodology and skill development courses have been introduced with a strong emphasis on practical learning. The inauguration ceremony also saw the participation of Dr V Sumathi, Associate Director of Regional Agricultural Research Station, Dr Jagapati Ramayya from the Veterinary College, as well as teaching and non-teaching staff, and students of the college.
&w=3840&q=100)
Business Standard
28-04-2025
- Business
- Business Standard
Dr Reddy's Laboratories, Sanofi Healthcare partner for respiratory drug
Hyderabad-based pharma company Dr Reddy's Laboratories has expanded its strategic partnership with Sanofi Healthcare India Private Limited (SHIPL) to introduce a novel drug, Beyfortus (nirsevimab), in the country. Used for treating respiratory syncytial virus (RSV), the drug is expected to launch in the second quarter of FY26. M V Ramana, chief executive officer, branded markets (India and emerging markets), Dr Reddy's, said, 'This partnership highlights our continued efforts to become the 'partner of choice' in bringing novel, innovative, and trusted drugs to patients. Beyfortus enables the access of healthcare professionals and parents to an improved drug in the prevention of RSV. Additionally, the launch of Beyfortus will help us strengthen our immunisation portfolio in India.' The drug, containing the monoclonal antibody nirsevimab, is delivered via a prefilled injection to prevent respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants during or entering their first RSV season. It is also administered to children up to 24 months who remain at risk during their second RSV season. Under the agreement, Dr Reddy's will have exclusive rights from SHIPL to promote and distribute Beyfortus within the country. This announcement follows Dr Reddy's exclusive distribution partnership with Sanofi for their portfolio of vaccines in India last year. 'Bringing Beyfortus to India is a pivotal step in our mission to protect every child from immunisation-preventable diseases like RSV. In India, where the disease burden is significant and early protection is critical, this collaboration with Dr Reddy's enables us to reach parents and healthcare providers with an innovative solution. Together, we are advancing equitable access to immunisation and improving preventive care for numerous children in India,' said Nitya Padmanabhan, head of Sanofi Vaccines (India). Beyfortus has been approved for use in the European Union, the US, China, Japan, and many other countries around the world. In India, Beyfortus received its marketing authorisation approval in June last year from the Central Drugs Standard Control Organisation (CDSCO). Dr Reddy's key therapeutic areas include gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Its major markets are the US, India, Russia and CIS countries, China, Brazil, and Europe.
